NK - NantKwest rises on positive interim data in metastatic pancreatic cancer trials

NantKwest (NK) +22.7% post-market after saying early interim results of its PD-L1 t-haNK protocols showed median survival rates more than doubled the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.The company says the trials appear to validate the theory that by orchestrating natural killer and T-cell therapy, survival rates could be improved without high-dose chemotherapy.In initial Cancer Moonshot QUILT trials of haNK and avelumabcompleted in 2019, the median overall survival rate more than doubled compared to historical controls; based on theencouraging early data, a single-arm Phase 2 study was initiated in October 2020, with overall survival as the primary endpoint, and 15 out of 18 patients enrolled with second-line or greater pancreatic cancer remain alive to date.Last month, NantKwest and partner ImmunityBio announced positive data in a Phase 2/3 bladder cancer trial.

For further details see:

NantKwest rises on positive interim data in metastatic pancreatic cancer trials